InSite Vision to Announce Fourth Quarter and Full Year 2007 Financial Results and Hold Conference Call on February 26, 2008

InSite Vision Incorporated (AMEX:ISV) announced today that it will release results for the fourth quarter and full year 2007 on Tuesday, February 26, 2008. S. Kumar Chandrasekaran, Ph.D., Chairman and Chief Executive Officer, will also host a conference call beginning at 4:30 p.m. Eastern Standard Time on Tuesday, February 26, 2008 to discuss these results. Analysts and investors can listen to the conference call by dialing (877) 407-0778 for domestic callers and (201) 689-8565 for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. All callers will need to enter the account number 286 and conference ID 275531. The live conference call will also be webcast and available at www.InvestorCalendar.com as well as on the Investor Relations page of the Company's website at www.insitevision.com. A recording of the call will be available for 90 days following completion of the conference call. In addition, the Company’s fourth quarter and full year 2007 earnings release will be posted to the Company’s web site and furnished to the Securities and Exchange Commission on a Form 8-K prior to the conference call described above. About InSite Vision InSite Vision develops novel anti-infective topical products including AzaSite (azithromycin ophthalmic solution) 1% for the topical treatment of bacterial conjunctivitis (pink eye), which was launched in the United States by Inspire Pharmaceuticals in August 2007. Based on its proprietary azithromycin-DuraSite® technology platform, InSite is expanding its portfolio of anti-infective ophthalmic products by developing AzaSite Plus™ and AzaSite Xtra™, whose product features have the potential to provide advantages not available with current treatment options. In addition, InSite is evaluating the use of its azithromycin-DuraSite platform to develop topical anti-infective products outside of the ophthalmology market, including the development of AzaSite Otic™ for ear infections.